Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Zollinger-Ellison Syndrome 1Wilms Tumor 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pinealoma 1Paraganglioma 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Insulinoma 1Hepatoblastoma 1Glucagonoma 1Glioma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Brain Stem Neoplasms 1Adrenocortical Carcinoma 1

Interventions

temsirolimus 1rofecoxib 1rindopepimut 1ovex 1imetelstat 1entinostat 1cixutumumab 1azurin (50-77) 1Re-Irradiation 1Quality of Life 1Piperazine 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Mebendazole 1Irinotecan 1Immunotherapy 1GRN163L peptide 1Everolimus 1Drug Therapy 1Dasatinib 1Cisplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Stem Neoplasms × cixutumumab × CNS × Clear all
NCT01182883 2017-07-02

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNS

Glioma, Pinealoma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡